Ottobock, Duderstadt, Germany, announced Philipp Schulte-Noelle will join the management team of the international medical technology manufacturer under CEO Oliver Scheel Dr. rer. nat. Dipl. Chem, starting August 15. He comes to Ottobock from Fresenius SE & Co. KGaA, Bad Homburg, Germany, where he began in 2013 as corporate business development/M&A; most recently he was CFO and labor director of Fresenius Kabi AG, an international supplier of generic intravenous drugs, clinical nutrition, infusion therapies, medical equipment, and infusion technology products.
Schulte-Noelle’s appointment completes the management board under majority shareholder Professor Hans Georg Näder. Scheel assumed the position of CEO on January 15 and assembled a new management team: Andreas Goppelt, PhD, is chief technology officer; he is responsible for research and development. Arne Jörn is COO; he began with the company in March. Ralf Stuch is CSMO; he is responsible for marketing and sales and will remain the interim CFO until Schulte-Noelle comes on board. “With the new CFO, we have put together a new management team within half a year, enabling us to work on our profitability and growth targets with a full line-up in the third quarter,” said Scheel.
Schulte-Noelle took over Corporate Business Development/M&A at in 2013. Since 2015 he has been CFO and labour director of Fresenius Kabi AG, with annual sales of EUR 6.4 billion (2017).
